Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 6/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | GRK5 | P34947 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5275390 | 0.89 | FKBP1A (0.39) | FKBP1A | |
| SCHEMBL4677132 | 0.87 | FKBP1A (0.40) | FKBP1A | |
| SCHEMBL5280472 | 0.84 | FKBP1A (0.51) | FKBP1A | |
| SCHEMBL4680570 | 0.82 | FKBP1A (0.47) | FKBP1A | |
| SCHEMBL4676173 | 0.81 | FKBP1A (0.41) | FKBP1A | |
| SCHEMBL5280412 | 0.80 | RIPK1 (0.37) | FKBP1A | |
| SCHEMBL5283101 | 0.79 | FKBP1A (0.36) | FKBP1A | |
| SCHEMBL4679856 | 0.78 | FKBP1A (0.37) | FKBP1A | |
| SCHEMBL6429261 | 0.78 | FKBP1A (0.37) | FKBP1A | |
| SCHEMBL5966030 | 0.77 | FKBP1A (0.49) | FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1626043-B1 | Heterocyclic thioesters | MGI GP INC (US) | 2007-12-12 | — | — | EP | claimed |
| EP-1900726-A1 | Heterocyclic thioesters | MGI GP, Inc. (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1626043-A1 | Heterocyclic thioesters | MGI GP, Inc. (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20050148637-A1 | Heterocyclic ketone and thioester compounds and uses | GPI NIL HOLDINGS, INC. | 2005-07-07 | — | — | US | disclosed |
| US-6218424-B1 | FOR EFFECTING NEURONAL ACTIVITIES IN ANIMALS, INCLUDING TREATING NEUROLOGICAL DISORDERS | GPI NIL HOLDINGS, INC. | 2001-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148637-A1 | Heterocyclic ketone and thioester compounds and uses | BDNF, NTRK2, NTRK1 | MEN1 3240/4885KMT2A 1423/4885FKBP1A 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.